These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23715301)

  • 61. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Prognostic evaluation of nutritional indicators in patients with limited-stage small cell lung cancer].
    Zhang JQ; Wang YY; Xu KP; Qi J; Wang X; Xu LM; Liu NN; Zhao LJ; Wang P
    Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):937-942. PubMed ID: 31874552
    [No Abstract]   [Full Text] [Related]  

  • 63. Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment.
    Manapov F; Klöcking S; Niyazi M; Belka C; Hildebrandt G; Fietkau R; Klautke G
    Strahlenther Onkol; 2012 Jan; 188(1):29-34. PubMed ID: 22189436
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
    Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
    J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.
    Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP; Khuri FR; Curran WJ; Ramalingam SS; Behera M; Higgins KA
    Clin Lung Cancer; 2019 Nov; 20(6):484-493.e6. PubMed ID: 31296433
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
    Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
    BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study.
    Sun M; Ji H; Deng F; Li J; Xu N; Li Y
    BMC Cancer; 2024 Sep; 24(1):1206. PubMed ID: 39350057
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy.
    Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Besen AA; Findikcioglu A; Ozyilkan O
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1123-1132. PubMed ID: 29887509
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
    Bogart J; Wang X; Masters G; Gao J; Komaki R; Gaspar LE; Heymach J; Bonner J; Kuzma C; Waqar S; Petty W; Stinchcombe TE; Bradley JD; Vokes E
    J Clin Oncol; 2023 May; 41(13):2394-2402. PubMed ID: 36623230
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy.
    Werner-Wasik M; Pequignot E; Leeper D; Hauck W; Curran W
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):689-96. PubMed ID: 11020565
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
    Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analysis of Once-Daily Thoracic Radiotherapy Dose According to the Underlying Lung Disease in Patients with Limited-Stage Small Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy.
    Kim BH; Chung JH; Son J; Kim S; Wu HG; Kim HJ
    Cancer Res Treat; 2023 Jan; 55(1):73-82. PubMed ID: 35287254
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis.
    Sun H; Liu C; Zhang J; Yang G; Han D; Liu T; Huang W; Li B
    Radiother Oncol; 2022 Jul; 172():140-146. PubMed ID: 35101460
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
    Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Twice-daily vs higher-dose once-daily thoracic radiotherapy for limited-disease small-cell lung cancer: A PRISMA-compliant meta-analysis.
    Yang L; Liu L; Yang Y; Lei Y; Wang T; Wu X; Guo X
    Medicine (Baltimore); 2020 Jul; 99(27):e20518. PubMed ID: 32629632
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy.
    Roengvoraphoj O; Eze C; Niyazi M; Li M; Hildebrandt G; Fietkau R; Belka C; Manapov F
    Strahlenther Onkol; 2017 Feb; 193(2):150-155. PubMed ID: 27853828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.